We investigated the immunological mechanisms and effects of berberine in the treatment of Alzheimer’s disease, revealing that berberine specifically binds to BACE1, one of the key targets in Alzheimer’s disease (Chu et al., 2018). Here, BACE1 is linked to early-onset autosomal dominant Alzheimer disease.